13,600 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Bought by Allostery Investments LP

Allostery Investments LP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 13,600 shares of the company's stock, valued at approximately $753,000. Tarsus Pharmaceuticals comprises approximately 0.8% of Allostery Investments LP's holdings, making the stock its 21st largest holding.

Several other hedge funds and other institutional investors also recently made changes to their positions in TARS. Summit Investment Advisors Inc. boosted its holdings in Tarsus Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after acquiring an additional 244 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $25,000. Bank of New York Mellon Corp boosted its stake in shares of Tarsus Pharmaceuticals by 0.5% in the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock valued at $5,644,000 after purchasing an additional 498 shares during the last quarter. Swiss National Bank grew its position in shares of Tarsus Pharmaceuticals by 1.2% during the 4th quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after buying an additional 600 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 10.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock worth $449,000 after buying an additional 789 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Down 5.8 %

NASDAQ TARS traded down $2.94 during trading hours on Friday, reaching $47.36. 992,443 shares of the company's stock were exchanged, compared to its average volume of 696,539. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -12.43 and a beta of 0.94. The company's 50-day moving average is $47.94 and its two-hundred day moving average is $48.90. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. On average, analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TARS has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Barclays dropped their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Oppenheimer boosted their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Guggenheim increased their price target on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday. Finally, Jefferies Financial Group lifted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $64.67.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 7,131 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the transaction, the chief executive officer now owns 70,720 shares of the company's stock, valued at approximately $3,273,628.80. This trade represents a 9.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the sale, the insider now owns 50,751 shares in the company, valued at $2,349,263.79. The trade was a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 in the last 90 days. 8.25% of the stock is currently owned by company insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.